Dynamic Changes of HER2 Expression in Breast Cancers after Neoadjuvant Chemotherapy with the Inclusion of HER2-low Category

被引：0
|
作者：
Karakas, Cansu [1 ]
Tyburski, Haley [2 ]
Liu, Elena [1 ]
Hicks, David [1 ]
Zhang, Huina [1 ]
机构：
[1] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
[2] Univ Rochester, Rochester, NY USA
来源：
LABORATORY INVESTIGATION | 2023年 / 103卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
163
引用
收藏
页码：S151 / S152
页数：2
相关论文
共 50 条
  • [41] Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer
    Yang, Yu-Feng
    Liao, Ying-Yang
    Li, Le-Qun
    Xie, Shu-Rui
    Xie, Yan-Fang
    Peng, Ning-Fu
    PATHOLOGY RESEARCH AND PRACTICE, 2013, 209 (12) : 797 - 802
  • [42] Response to anti-HER2 neoadjuvant chemotherapy in HER2-positive invasive breast cancers with different HER2 FISH patterns
    Lv, Hong
    Bai, Qian-Ming
    Li, Ming
    Cai, Meng-Yuan
    Zhou, Shu-Ling
    Liu, Yin
    Wang, Zhong-Hua
    Shui, Ruo-Hong
    Lu, Hong-Fen
    Xu, Xiao-Li
    Yu, Bao-Hua
    Tu, Xiao-Yu
    Bi, Rui
    Cheng, Yu-Fan
    Zhou, Xiao-Yan
    Shao, Zhi-Min
    Yang, Wen-Tao
    JOURNAL OF CLINICAL PATHOLOGY, 2024,
  • [43] HER2-LOW POSITIVE AND HER2-ZERO BREAST CANCERS ARE CLINICALLY DISTINCT
    不详
    CANCER DISCOVERY, 2021, 11 (09) : 2124 - 2124
  • [44] Changes in HER2 status after neoadjuvant treatment of breast cancer
    Skalova, H.
    Dundr, P.
    Povysil, C.
    Pribylova, O.
    Petruzelka, L. B.
    Tvrdik, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] Predictors of Response to Trastuzumab Containing Neoadjuvant Chemotherapy in HER2 Positive Breast Cancers
    Li, X.
    Kanbour-Shakir, A.
    Dabbs, D.
    Bhargava, R.
    MODERN PATHOLOGY, 2012, 25 : 49A - 50A
  • [46] Predictors of Response to Trastuzumab Containing Neoadjuvant Chemotherapy in HER2 Positive Breast Cancers
    Li, X.
    Kanbour-Shakir, A.
    Dabbs, D.
    Bhargava, R.
    LABORATORY INVESTIGATION, 2012, 92 : 49A - 50A
  • [47] HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles
    Zhang, Huina
    Katerji, Hani
    Turner, Bradley M.
    Audeh, William
    Hicks, David G.
    MODERN PATHOLOGY, 2022, 35 (08) : 1075 - 1082
  • [48] Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
    Zhou, Shuling
    Liu, Ting
    Kuang, Xiaying
    Zhen, Tiantian
    Shi, Huijuan
    Lin, Ying
    Shao, Nan
    BREAST, 2023, 67 : 1 - 7
  • [49] Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
    Zhou, Shuling
    Liu, Ting
    Kuang, Xiaying
    Zhen, Tiantian
    Shi, Huijuan
    Lin, Ying
    Shao, Nan
    BREAST, 2023, 67 : 1 - 7
  • [50] Genomic Alterations of Tumors in HER2-Low Breast Cancers
    Tsai, Yi-Fang
    Huang, Chi-Cheng
    Hsu, Chih-Yi
    Feng, Chin-Jung
    Lin, Yen-Shu
    Chao, Ta-Chung
    Lai, Jiun-, I
    Lien, Pei-Ju
    Liu, Chun-Yu
    Chiu, Jen-Hwey
    Tseng, Ling-Ming
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (02)
12345